Drugs / YYC506-A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04874129 | Jan → May 2021 | hyperlipidemia | Yooyoung Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04874142 | Nov 2019 → Mar 2020 | hyperlipidemia | Yooyoung Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YYC506-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04874129 ↗ |
| Route | Oral | “multiple oral dosing” NCT04874142 ↗ |